Evidence map›Paper›PMID 42099237›Full record

ArticleInternational journal of molecular medicine2026

[Expression of Concern] ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple‑negative breast cancer cells.

Yang Zhang, Lu Wang, Peng Gao, Zhiguo Sun, Ning Li, Yanqin Lu, Jianglun Shen, Jian Sun, Yiming Yang, Hao Dai and 1 more

Abstract readExpression of Concern
In one paragraph

Article in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Yang ZhangThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Lu WangThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Peng GaoThe Second Department of Chemoradiotherapy, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Zhiguo SunThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Ning LiThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Yanqin LuThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Jianglun ShenThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Jian SunThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Yiming YangThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Hao DaiThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.
Haifeng CaiThe Second Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that, regarding the cell invasion assay experiments shown in Fig. 3A, B and C on p. 2348, two pairs of data panels were overlapping, such that data which were intended to show the results from differently performed experiments had apparently been derived from a smaller number of original sources. In addition, an independent investigation of the data in this paper undertaken by the Editorial Office revealed that flow cytometric data in Fig. 4A were shared with a paper that was published in the journal

Indexed as

CisplatinDrug Resistance, NeoplasmLIM-Homeodomain ProteinsTranscription FactorsTriple Negative Breast NeoplasmsAntineoplastic AgentsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsCisplatinLIM-Homeodomain ProteinsTranscription Factorscancer progressioncisplatin sensitivityislet 1triple-negative breast cancer

Identifiers

PMID42099237
PMCPMC13170774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.